This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

SPC5001

Roche Holding AG

Drug Names(s): SPC-5001, SPC 5001

Description: SPC5001 is a RNA-targeted drug inhibiting PCSK9, which is a protein involved in removing low-density lipoprotein cholesterol (LDL-C).

In preclinical studies, SPC5001 provided fast-acting, potent and long-lasting inhibition of PCSK9 and provided reductions of mean LDL cholesterol by 50% in non-human primates with a sustained reduction of 74% in the highest responder. SPC5001 did not change HDL (high-density lipoprotein) levels.

Deal Structure: Roche and Santaris
In August 2014, Roche announced that it has agreed to acquire Santaris Pharma. Roche plans to maintain Santaris Pharmas operations in Denmark, where the existing site will be renamed Roche Innovation Center Copenhagen. Under the terms of the agreement, Roche will make an upfront cash payment of USD 250 million to Santaris Pharma shareholders and make additional contingent payments of up to USD 200 million based on the achievement of certain predetermined milestones.


SPC5001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug